Novo Nordisk accuses rival companies of foul play
![Foto: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article3000868.ece/ALTERNATES/schema-16_9/img0021.Novo.PR.jpg)
It is a battle to the death to win and maintain market shares on the valuable diabetes market. And during the course of that battle competitors are met with unfair methods and persistent price war, according to Danish newspaper Berlingske.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.